Vol. 67, No. 12 (2019)
Chem. Pharm. Bull.
1345
4.31 (1H, dd, J=8.9, 8.7Hz, H-3′), 4.23 (1H, dd, J=8.7,
(R)-MTPA ester of 5 (5a): amorphous powder; 1H-NMR
8.1Hz, H-2′), 4.11 (1H, ddd, J=11.1, 9.6, 4.3Hz, H-2), 4.04 (600MHz, CDCl3) δ: 7.35–7.55 (5H, m, aromatic protons), 6.05
(1H, ddd, J=9.5, 4.4, 2.4Hz, H-5′), 3.93 (1H, dd, J=10.7, (1H, d, J=15.2Hz, H-7), 6.02 (1H, dd, J=15.2, 4.9Hz, H-8),
2.9Hz, H-30a), 3.88 (1H, dd, J=10.7, 5.6Hz, H-30b), 3.39 5.66 (1H, qd, J=6.5, 4.9Hz, H-9), 5.44 (1H, dddd, J=10.5,
(1H, d, J=9.4Hz, H-3), 2.65 (1H, d, J=11.5Hz, H-18), 2.49 10.5, 7.2, 7.2Hz, H-3), 3.87 (1H, d, J=8.2Hz, H-12a), 3.77
(1H, ddd, J=13.8, 13.7, 4.4Hz, H-15a), 2.26 (1H, dd, J=12.5, (1H, dd, J=8.2, 2.0Hz, H-12b), 3.53 (3H, s, –OMe), 3.51 (3H,
4.4Hz, H-1a), 2.21 (1H, ddd, J=13.5, 13.4, 4.2Hz, H-16a), s, –OMe), 2.18 (1H, ddd, J=13.6, 7.2, 1.5Hz, H-4), 2.03 (1H,
2.07 (1H, m, H-22a), 2.06 (1H, m, H-16b), 2.05 (2H, m, H2-11), ddd, J=13.6, 7.2, 1.5Hz, H-2), 1.73 (1H, dd, J=13.6, 10.5Hz,
2.01 (1H, m, H-19), 1.86 (2H, m, H2-21), 1.84 (1H, m, H-22b), H-4), 1.70 (1H, ddd, J=13.6, 10.5, 2.0Hz, H-2), 1.45 (3H, d,
1.74 (1H, dd, J=10.0, 7.4Hz, H-9), 1.54 (1H, m, H-7a), 1.52 J=6.5Hz, H3-10), 1.08 (3H, s, H3-13), 0.90 (3H, s, H3-11); HR-
(1H, m, H-6a), 1.40 (1H, m, H-7b), 1.38 (1H, m, H-6b), 1.27 ESI-MS (positive-ion mode) m/z: 697.2206 [M+Na]+ (Calcd
(1H, m, H-1b), 1.26 (3H, s, H3-23), 1.20 (3H, s, H3-27), 1.19 for C33H36O8F6Na: 697.2207).
(3H, s, H3-26), 1.18 (1H, m, H-15b), 1.16 (1H, m, H-20), 1.11
(S)-MTPA ester of 5 (5b): amorphous powder; 1H-NMR
(3H, d, J=6.4Hz, H3-29), 1.09 (3H, s, H3-24), 1.04 (3H, s, (600MHz, CDCl3) δ: 7.35–7.55 (10H, m, aromatic protons),
H3-25), 1.01 (1H, d, J=12.1Hz, H-5); 13C-NMR (150MHz, 6.11 (1H, d, J=15.5Hz, H-7), 6.08 (1H, dd, J=15.5, 5.5Hz,
pyridine-d5): Table 2; HR-ESI-MS (positive-ion mode) m/z: H-8), 5.63 (1H, qd, J=6.5, 5.5Hz, H-9), 5.44 (1H, dddd,
673.3925 [M +Na]+ (Calcd for C36H58O10Na: 673.3922).
J=10.7, 10.7, 7.1, 7.1Hz, H-3), 3.88 (1H, d, J=8.3Hz, H-12a),
30-O-β-D- 3.78 (1H, dd, J=8.3, 2.1Hz, H-11b), 3.52 (3H, s, –OMe), 3.49
2α,3β,30-Trihydroxyurs-12-en-28-oic
acid
glucopyranoside (4b): Amorphous powder; [α]D25 +5.5 (3H, s, –OMe), 2.25 (1H, ddd, J=13.6, 7.1, 1.5Hz, H-4), 1.99
(c=0.10, MeOH); IR νmax (film) cm−1: 3370, 2930, 2871, (1H, ddd, J=13.6, 7.1, 1.5Hz, H-2), 1.85 (1H, ddd, J=13.6,
1686, 1457, 1050; 1H-NMR (600MHz, pyridine-d5) δ: 5.45 10.7Hz, H-4), 1.62 (1H, ddd, J=13.6, 10.7, 2.1Hz, H-2),
(1H, dd, J=3.1, 3.1Hz, H-12), 4.90 (1H, d, J=7.8Hz, H-1″), 1.40 (3H, d, J=6.5Hz, H3-10), 1.10 (3H, s, H3-13), 0.91 (3H,
4.62 (1H, dd, J=11.7, 2.2Hz, H-6″a), 4.45 (1H, dd, J=11.7, s, H3-11); HR-ESI-MS (positive-ion mode) m/z: 697.2206
5.3Hz, H-6″b), 4.30 (1H, dd, J=8.8, 8.9Hz, H-3″), 4.27 (1H, [M+Na]+ (Calcd for C33H36O8F6Na: 697.2207).
dd, J=8.9, 8.9Hz, H-4″), 4.10 (1H, m, H-2), 4.09 (1H, m,
NaBH4 Reduction of 6 To a solution of 6 (11.0mg) in
H-2″), 4.07 (1H, m, H-30a), 4.03 (1H, m, H-5″), 3.89 (1H, dd, MeOH (1mL) was added 8.2mg of NaBH4 and the reaction
J=9.5, 3.5Hz, H-30b), 3.40 (1H, d, J=9.4Hz, H-3), 2.65 (1H, mixture was stirred for 5min at 25°C. Excess NaBH4 was
d, J=11.3Hz, H-18), 2.32 (1H, ddd, J=13.8, 13.8, 4.4Hz, quenched by the addition of 1mL of acetone and then the
H-15a), 2.24 (1H, dd, J=12.5, 4.4Hz, H-1a), 2.07 (1H, m, reaction mixture was evaporated to dryness. The resultant
H-16a), 2.04 (1H, m, H-21a), 2.03 (1H, m, H-22a), 2.02 (2H, residue was purified by HPLC [Inertsil ODS-3, 6×250mm,
m, H2-11), 1.96 (1H, m, H-16b), 1.94 (1H, m, H-22b), 1.75 H2O–MeOH (1:4), flow rate: 1.6mL/min] to give 3.1mg of
(2H, m, H-9 and 19), 1.66 (1H, m, H-21b), 1.55 (1H, m, H-6a), 6c (=5) and 5.8mg of 6d from the peaks at 10.9min and
1.54 (1H, m, H-7a), 1.39 (1H, m, H-20), 1.38 (1H, m, H-6b), 13.3min. respectively.
1.37 (1H, m, H-7b), 1.28 (3H, s, H3-23), 1.28 (1H, m, H-1b),
Compound 6c: amorphous powder; [α]D24 +7.1 (c=0.31,
1.17 (3H, s, H3-27), 1.16 (1H, m, H-15b), 1.08 (3H, s, H3-24), MeOH); HR-ESI-MS (positive-ion mode) m/z: 265.1409
1.04 (3H, s, H3-26), 1.03 (1H, m, H-5), 1.01 (3H, d, J=6.4Hz, [M+Na]+ (Calcd for C13H22O4Na: 265.1410).
H3-29), 0.98 (3H, s, H3-25); 13C-NMR (150MHz, pyridine-
Compound 6d: amorphous powder; [α]D24 −5.5 (c=0.29,
d5): Table 2; HR-ESI-MS (positive-ion mode) m/z: 649.3948 MeOH); IR νmax (film) cm−1: 3402, 2929, 2889, 1604, 1453,
[M−Na]− (Calcd for C30H57O10: 649.3946).
1381, 1101, 1053; H-NMR (600MHz, CD3OD) δ: 6.02 (1H,
1
2α,3β,30-Trihydroxyurs-12-en-28-oic acid (4c): Amorphous dd, J=15.5, 5.6Hz, H-8), 5.82 (1H, dd, J=15.5, 1.0Hz, H-7),
powder; [α]D23 +17.7 (c=0.13, EtOH); HR-ESI-MS (positive- 4.33 (1H, qd, J=6.4, 5.6Hz, H-9), 4.12 (1H, d, J=6.9Hz,
ion mode) m/z: 487.3423 [M−H]− (Calcd for C30H47O5: H-12a), 4.02 (1H, dd, J=5.7, 5.7Hz, H-3), 3.76 (1H, dd,
487.3418).
J=6.9, 2.3Hz, H-12b), 2.13 (1H, dd, J=15.5, 5.7Hz, H-4a),
Preparation of (R)- and (S)-MTPA Esters (5a and 5b) 2.02 (1H, ddd, J=15.3, 5.7, 2.2Hz, H-2a), 1.84 (1H, dd,
from 5 A solution of 5 (1.0mg) in 0.5mL of dry CH2Cl2 J=15.5, 2.2Hz, H-4b), 1.73 (1H, dd, J=15.3, 2.3Hz, H-2b),
were reacted with (R)-MTPA (21.5mg) in the presence of 1.25 (3H, d, J=6.4Hz, H3-10), 1.13 (3H, s, H3-13), 0.86 (3H,
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
hydrochlo- s, H3-11); 13C-NMR (150MHz, CD3OD) δ: 139.4 (C-8), 126.8
ride (EDC) (13.4mg) and N,N-dimethyl-4-aminopyridine (C-7), 87.2 (C-5), 82.5 (C-6), 76.3 (C-12), 69.1 (C-9), 66.0
(4-DMAP) (16.1mg). The mixture was then occasionally (C-3), 48.0 (C-1), 45.1 (C-4), 44.9 (C-2), 24.1 (C-10), 19.7
stirred at 37°C for 24h. After the addition of CHCl3 (1.5mL), (C-13), 16.3 (C-11); HR-ESI-MS (positive-ion mode) m/z:
the reaction mixture was successively washed with H2O 265.1408 [M+Na]+ (Calcd for C13H22O4Na: 265.1410).
(1mL), 1M HCl (1mL), NaHCO3-saturated H2O (1mL), and
Cytotoxic Activity toward Human Lung Adenocarci-
brine (1mL). The organic layer was dried with Na2SO4 and noma, A549 Cells Cytotoxic activity toward lung adeno-
evaporated under reduced pressure. The residue was purified carcinoma cells was determined by colorimetric cell viability
by preparative TLC [silica gel (0.25mm thickness), being ap- assay using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
plied for 8cm width, with development with CHCl3–MeOH lium bromide (MTT). Lung adenocarcinoma cell line A549
(19:1) for 9cm and then eluting with CHCl3–MeOH (1:1)] was purchased from the JCRB Cell Bank, Japan. A549
to furnish an ester 5a (0.5mg) from the band at Rf =0.67. cells were cultured in Dulbecco’s modified Eagle’s medium
Through the same procedure, 5b (0.6mg, Rf =0.59) were supplemented with 10% heat inactivated FCS, and kanamycin
prepared from 5 (1.0mg) using (S)-MTPA (25.4mg), EDC (100 µg/mL) and amphotericin B (5.6µg/mL). In a 96-well
(15.8mg), and 4-DMAP (15.5mg), respectively.
plate, 1µL aliquots of sample solutions and the cancer cells